Reinsurance Group of America Ranked #196 on the 2025 Fortune 500 List
ST. LOUIS--(BUSINESS WIRE)-- Reinsurance Group of America, Incorporated (NYSE: RGA), a leading global life and health reinsurer, announced today it has been ranked #196 on the 2025 Fortune 500 list, moving up 27 positions from its 2024 rank and breaking into the top 200 for the first time. The annual list, which ranks US-based companies by total revenue, appears in the June/July issue of Fortune magazine.
This achievement, made possible by our incomparable team in the US and worldwide, underscores our strong momentum.
Share
'RGA's ascent to the top 200 in the Fortune 500 rankings signifies more than growth—it illustrates our enduring commitment to empower financial security and peace of mind globally,' said Tony Cheng, President and CEO, RGA. 'This achievement, made possible by our incomparable team in the US and worldwide, underscores our strong momentum. By focusing on client relationships and innovative solutions, we continue to lead the way in expanding financial protection and delivering value to our clients and stakeholders.'
As the only global reinsurer exclusively dedicated to life and health, RGA has consistently expanded its reach and influence. RGA premiered on the Fortune 500 ranking in 2010 at #321 and has significantly improved its position, rising 125 spots since its debut. RGA's growth underscores its mission-driven approach and commitment to providing meaningful financial solutions that support individuals and families worldwide.
About RGA
Reinsurance Group of America, Incorporated (NYSE: RGA) is a global industry leader specializing in life and health reinsurance and financial solutions that help clients effectively manage risk and optimize capital. Founded in 1973, RGA is today one of the world's largest and most respected reinsurers and remains guided by a powerful purpose: to make financial protection accessible to all. As a global capabilities and solutions leader, RGA empowers partners through bold innovation, relentless execution, and dedicated client focus — all directed toward creating sustainable long-term value. RGA has approximately $4.0 trillion of life reinsurance in force and assets of $128.2 billion as of March 31, 2025. To learn more about RGA and its businesses, please visit rgare.com or follow RGA on LinkedIn and Facebook. Investors can learn more at investor.rgare.com.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
22 minutes ago
- Yahoo
Sydnexis Announces European Commission Approval of SYD-101, the First and Only Pharmaceutical Treatment for Slowing the Progression of Pediatric Myopia
Exclusive-Licensing Partner Santen Will Commercialize SYD-101 Under the Brand Name Ryjunea® in the European Union DEL MAR, Calif., June 05, 2025--(BUSINESS WIRE)--Sydnexis, Inc., ( a pre-commercial stage biopharmaceutical company today announced that the European Commission (EC) has granted marketing authorization for SYD-101, the company's proprietary low-dose atropine formulation, for slowing the progression of pediatric myopia. As the first and only approved pharmaceutical treatment option to treat myopia progression in EU countries, this approval marks a significant advancement in pediatric eye care. The approval is backed by data from the STAR study, Sydnexis' pivotal Phase 3 clinical trial evaluating its proprietary low-dose atropine formulation to slow the progression of pediatric myopia and the risk of associated co-morbidities in children 3 to 14 years old at treatment initiation. "This marks a significant milestone for Sydnexis and, most importantly, for pediatric patients with progressive myopia, their families, and physicians as the first and only approved pharmaceutical treatment option in Europe," said Perry Sternberg, Chief Executive Officer of Sydnexis. "This approval is an endorsement of the potential benefit SYD-101 can provide to millions of patients globally and reinforces the critical importance of early intervention." The marketing approval from the EC follows the recent positive opinion from the Committee for Medicinal Products for Human Use (CHMP). Santen, a Japan-based company specialized in eye health, offering innovative products and services in over 60 countries worldwide, licensed the rights from Sydnexis to commercialize SYD-101 in the regions of Europe, Middle East, and Africa (EMEA) and will launch SYD-101 under the brand name Ryjunea. "The EU approval of SYD-101 is a recognition of the compelling safety and efficacy data generated from our landmark STAR study," said Patrick Johnson, Ph.D., President of Sydnexis. "This validates the potential benefit that SYD-101 can provide to pediatric myopes in Europe and we are excited about our continued interactions with the Food and Drug Administration (FDA) leading up to our October 23 PDUFA date." Myopia is the most common eye disease in children, impacting approximately one-third of children and adolescents worldwide. By 2050, global prevalence is projected to increase and affect more than 740 million children and adolescents and 5 billion people in total. Once considered a benign refractive condition, even at low levels, myopia is now associated with many serious irreversible sight-threatening co-morbidities later in life. "As a Pediatric Ophthalmologist with a rapidly growing number of myopia patients around the world, the EU approval of SYD-101 is truly exciting and it provides an important new tool for physicians to combat this global epidemic," said Dr. Donny Suh, Gavin Herbert Eye Institute, University of California at Irvine. "The benefits of low-dose atropine have long been recognized in the eye care community, but we now finally have an approved and thoroughly vetted treatment option. This marks a new era in our ability to slow the progression of myopia and protect the vision of millions of children worldwide." About Sydnexis, Inc.: Founded in 2014, Sydnexis, Inc. ( is a privately held, pre-commercial stage biopharmaceutical company based in San Diego, California. Sydnexis recently completed its three-year primary endpoint in the pivotal Phase 3 clinical trial evaluating its proprietary low-dose atropine formulation to slow progression of pediatric myopia and the risk of associated co-morbidities. The Phase 3 clinical trial is now completing the fourth-year randomized withdrawal for exploratory endpoints and third year results will be announced upon completion of the fourth year of the study. The company is venture-backed by four major investors: Visionary Ventures, RA Capital, Longitude Capital, and Bluestem Capital. View source version on Contacts For media inquiries, please contact: media@
Yahoo
22 minutes ago
- Yahoo
Oshkosh Corporation Hosting 2025 Investor Day
OSHKOSH, Wis., June 05, 2025--(BUSINESS WIRE)--Oshkosh Corporation (NYSE: OSK), a leading innovator of purpose-built vehicles and equipment, is hosting its Investor Day today, June 5, 2025, at the New York Stock Exchange beginning at 9:30 a.m. EDT. Register for the full live event here: Live webcast (register/join). The presentations will provide an in-depth review of Oshkosh's business strategy, growth drivers and financial objectives. During the event, there will be an opportunity for both live and webcast attendees to ask questions during a Q&A session. Event presentations will proceed as follows: Oshkosh Corporation overview John Pfeifer, president & CEO Technology for Everyday Heroes Jay Iyengar, EVP, chief technology & strategic sourcing officer Access segment Mahesh Narang, EVP & president, Access segment Transport segment John Pfeifer, president & CEO Vocational segment Mike Pack, EVP & president, Vocational segment Financial Matthew Field, EVP & CFO Closing remarks and Q&A Oshkosh leadership team A portion of today's presentation will be available starting at 8:00 a.m. EDT here: The full presentation will be available at approximately 11:15 am EDT at the same link. A replay of the webcast will be available under the "Events & Presentations" section of the company's Investor Relations website shortly following the conclusion of the event. About Oshkosh Corporation At Oshkosh (NYSE: OSK), we make innovative, mission-critical equipment to help everyday heroes advance communities around the world. Headquartered in Wisconsin, Oshkosh Corporation employs over 18,000 team members worldwide, all united behind a common purpose: to make a difference in people's lives. Oshkosh products can be found in more than 150 countries under the brands of JLG®, Pierce®, MAXIMETAL, Oshkosh® S-Series™, McNeilus®, IMT®, Jerr-Dan®, Frontline™ Communications, Oshkosh® Airport Products, Oshkosh AeroTech™, Oshkosh® Defense and Pratt Miller. For more information, visit ®, ™ All brand names referred to in this news release are trademarks of Oshkosh Corporation or its subsidiary companies. View source version on Contacts Financial:Patrick DavidsonSenior Vice President, Investor Relations920.502.3266 Media:Tim GilmanSenior Manager, Communications and Branding920.509.0617 Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Business Wire
25 minutes ago
- Business Wire
The Cherry on Top: JetBlue Launches Service to Cherry Capital Airport in Traverse City, Michigan
BOSTON--(BUSINESS WIRE)--JetBlue (NASDAQ: JBLU) today announced the start of its summer-seasonal service between Boston Logan International Airport (BOS) and Cherry Capital Airport (TVC) in Traverse City, Mich. Taking off today and operating Thursdays, Saturdays and Sundays through October 25, the new service connects New England with one of the nation's top summer vacation destinations. The new route also gives Northern Michiganders access to JetBlue's extensive focus city network from Boston, where the airline serves more destinations than any other carrier. To celebrate, tickets between Boston and Traverse City are now on sale, with fares starting as low as $69 when booking on 1 'Traverse City might be one of the best-kept summer secrets, and JetBlue is excited to make it more accessible to travelers,' said David Jehn, vice president network plan and airline partnerships at JetBlue. 'This new route reflects our commitment to connecting more people to unique and underserved destinations. By adding Traverse City to our map, we're not only opening the door for New Englanders to discover Northern Michigan's natural beauty but also giving locals easier access to Boston and JetBlue's broader network.' "We're thrilled to welcome JetBlue to the TVC route map! This exciting addition enhances our connectivity to Boston and the East Coast, opening new opportunities for both regional travelers and visitors discovering all that northern Michigan has to offer," said Kevin Klein, CEO of Cherry Capital Airport. "This expansion not only enhances travel options but also strengthens the visitor economy—an essential driver of prosperity for our region. Supporting tourism and connectivity is vital to our continued growth, and this new addition marks another step forward for our community," said Trevor Tkach, President & CEO of Traverse City Tourism. The Cherry on Top Nestled along Grand Traverse Bay, Traverse City brings the quaint feeling of a coastal community to the Midwest. From the hiking trails of Sleeping Bear Dunes National Lakeshore to the soft sand and towering lighthouses overlooking the waters of Lake Michigan's – not to mention the thriving food and drink culture – Traverse City offers something for any summer traveler. And, with its namesake cherry orchards in full bloom, summer is that much sweeter in Traverse City. Customers traveling from Traverse City now have access to cities across JetBlue's network, through the airline's leading presence in Boston. As New England's leading leisure carrier, JetBlue has made Boston a key part of its network strategy as it delivers on its commitment of building the best East Coast leisure network, most recently reflected in the launch of service from Boston to Madrid, Spain, and Edinburgh, Scotland, which customers can enjoy through the summer season. Schedule between Boston and Traverse City Operating Thursdays, Saturdays and Sundays from June 5, 2025 - October 25, 2025 BOS - TVC Flight #1263 TVC- BOS Flight #1264 9:40 AM - 11:56 AM 12:45 PM - 2:47 PM Expand Flights to Traverse City will operate on JetBlue's spacious A220 aircraft, offering customers JetBlue's award-winning service, fast and free Fly-Fi®, seatback entertainment at every seat, and complimentary snacks and drinks. 2 Book better with JetBlue To celebrate today's launch, and for a limited time, customers can take advantage of special $69 one-way fares for flights between Boston and Traverse City available online only on Customers who book directly through are guaranteed to find our lowest fares, and can enjoy additional benefits including access to all of JetBlue's fare options, as well as fare sales and promotions, some of which may not be available through other third parties; the ability to earn 2x TrueBlue points and participate in Points Pooling; seamless seat selections and upgrades to EvenMore ®; 24/7 direct access to JetBlue's customer service channels; and more. About JetBlue JetBlue is New York's Hometown Airline ®, and a leading carrier in Boston, Fort Lauderdale-Hollywood, Los Angeles, Orlando and San Juan. JetBlue carries customers to more than 100 destinations throughout the United States, Latin America, Caribbean, Canada and Europe. For more information and the best fares, visit 1. Boston to Traverse City: One-way only. Book by 6/6/2025 for travel 6/15/2025 – 10/25/2025. Sunday travel only. Seven-day advance purchase required. Traverse City to Boston: One-way only. Book by 6/6/2025 for travel 6/19/2025 - 10/25/2025. Thursday, Saturday travel only. Blackout dates: 7/17/2025 - 8/16/2025. Seven-day advance purchase required. 2. Fly-Fi ® and live television are available on all JetBlue-operated flights. Availability and coverage area may vary by aircraft. Details on inflight wi-fi and entertainment:
